Altimmune's full July 28 RECLAIM readout puts a number on what the top-line only promised: patients on pemvidutide cut heavy-drinking days by 4.20 versus 2.75 on placebo, a 1.45-day advantage with p=0.0014. [1]

A day earlier, the paper's July 28 account held the sponsor's primary-endpoint claim inside its trial design, keeping magnitude, safety, and clinical meaning visible as open questions. The full numbers answer the first of those; the rest stay open. [2]

The detail runs both ways. In the treatment arm, 42.2% of patients reached zero heavy-drinking days against 17.4% on placebo, a phosphatidylethanol biomarker fell, and patients lost 9.1% of weight placebo-adjusted — but one possibly drug-related serious adverse event, hyponatremia, entered the record, and roughly 20% of participants discontinued. [1]

The population was about 100 patients with BMI above 25, and Fierce Biotech's "unequivocal" frame came with a +10% premarket stock move — trade-press enthusiasm, not independent review. [2] Reuters's measured wire reported the same endpoint without the adjective. [3]

Altimmune said it plans to seek a meeting with the Food and Drug Administration — a proposed regulatory discussion, not a phase 3 program, filing, approval, price, or access decision. The confidence intervals and the full adverse-event table remain unpublished in the July-29-safe record. [3]

Cross-trial comparison to semaglutide is challenging per Leerink, and phase 3, replication, abstinence outcomes, approval, and treatment advice all remain unestablished. Magnitude now exists; significance in a small mid-stage trial still cannot carry a breakthrough claim.

-- NORA WHITFIELD, Chicago